BG
ISEE

Bellevue Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bellevue Group’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-52,900
Closed -$1.29M – 167
2023
Q1 		$1.29M Buy
52,900
+11,100
+27% +$243K 0.02% 124
2022
Q4 		$895K Buy
+41,800
New +$892K 0.01% 137

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Bellevue Group's ISEE Position: Q2 2023 in Review

Bellevue Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 52,900 shares — an estimated $1.29M sold.

Bellevue Group first reported a position in ISEE in Q4 2022 and held it in 2 quarters. The position peaked at $1.29M in Q1 2023. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • Bellevue Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bellevue Group sold 52,900 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $1.29M.
  • Bellevue Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Bellevue Group's IVERIC bio, Inc. Common Stock position peaked at $1.29M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.